Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Archana Narasanna"'
Autor:
Carlos L. Arteaga, Craig W. Lindsley, J. Phillip Kennedy, Rebecca S. Cook, Archana Narasanna, Nara de Matos Granja, Teresa C. Dugger, Violeta Sanchez, Maria G. Olivares, H. Charles Manning, Shelby K. Wyatt, Chirayu Shah, James T. Forbes, Todd W. Miller
Supplementary Data from Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653c8b21d3c6a201c988ec0973ac57a0
https://doi.org/10.1158/1078-0432.22440382
https://doi.org/10.1158/1078-0432.22440382
Autor:
Carlos L. Arteaga, Jeffrey A. Engelman, Youngchul Song, Anindita Chakrabarty, Mónica Valeria Estrada, Archana Narasanna, Ritwik Ghosh, Brent N. Rexer
Supplementary Figure 7 - PDF file 282K, Inhibition of P-Akt in xenografts treated with trastuzumab plus/minus lapatinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe45046d0757c4020ef5cd3b87e5598
https://doi.org/10.1158/1078-0432.22448756.v1
https://doi.org/10.1158/1078-0432.22448756.v1
Autor:
Carlos L. Arteaga, Jeffrey A. Engelman, Youngchul Song, Anindita Chakrabarty, Mónica Valeria Estrada, Archana Narasanna, Ritwik Ghosh, Brent N. Rexer
Supplementary Figure Legends - PDF file 98K, Legends for supplementary figures 1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59a0c26fdc8b0e06c1e551a12c6551fc
https://doi.org/10.1158/1078-0432.22448753
https://doi.org/10.1158/1078-0432.22448753
Autor:
Carlos L. Arteaga, Jeffrey A. Engelman, Youngchul Song, Anindita Chakrabarty, Mónica Valeria Estrada, Archana Narasanna, Ritwik Ghosh, Brent N. Rexer
Supplementary Figure 2 - PDF file 141K, Expression of T798M HER2 results in increased HER3 phosphorylation and HER3-p85 association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::069a59186150f9fcecf1fbcb73d60148
https://doi.org/10.1158/1078-0432.22448771
https://doi.org/10.1158/1078-0432.22448771
Autor:
Carlos L. Arteaga, Jeffrey A. Engelman, Youngchul Song, Anindita Chakrabarty, Mónica Valeria Estrada, Archana Narasanna, Ritwik Ghosh, Brent N. Rexer
Supplementary Figure 5 - PDF file 77K, HER3 expression is required for growth of T798M mutant-expressing cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f4024bad16d0d82bbd00c0f396d63ab
https://doi.org/10.1158/1078-0432.22448762.v1
https://doi.org/10.1158/1078-0432.22448762.v1
Autor:
Carlos L. Arteaga, Jeffrey A. Engelman, Youngchul Song, Anindita Chakrabarty, Mónica Valeria Estrada, Archana Narasanna, Ritwik Ghosh, Brent N. Rexer
Supplementary Figure 4 - PDF file 152K, T798M mutant expression in as low as 5% of cells is sufficient to confer resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f385991b2e3caf16d4ff0815624dc8
https://doi.org/10.1158/1078-0432.22448765
https://doi.org/10.1158/1078-0432.22448765
Autor:
Carlos L. Arteaga, Craig W. Lindsley, J. Phillip Kennedy, Rebecca S. Cook, Archana Narasanna, Nara de Matos Granja, Teresa C. Dugger, Violeta Sanchez, Maria G. Olivares, H. Charles Manning, Shelby K. Wyatt, Chirayu Shah, James T. Forbes, Todd W. Miller
Purpose: A significant fraction of HER2-overexpressing breast cancers exhibit resistance to the HER2 antibody trastuzumab. Hyperactivity of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway confers trastuzumab resistance, and mammalian target of r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a00d9dac82eb35707c35f191fbcf914d
https://doi.org/10.1158/1078-0432.c.6517720
https://doi.org/10.1158/1078-0432.c.6517720
Autor:
Carlos L. Arteaga, Jeffrey A. Engelman, Youngchul Song, Anindita Chakrabarty, Mónica Valeria Estrada, Archana Narasanna, Ritwik Ghosh, Brent N. Rexer
Supplementary Figure 1 - PDF file 189K, Pan-ErbB inhibitor CI-1033 inhibits HER2 phosphorylation and cell growth of both wild-type and T798M mutant cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6079e4cd3ca7752fa7232c88c2920f39
https://doi.org/10.1158/1078-0432.22448774.v1
https://doi.org/10.1158/1078-0432.22448774.v1
Autor:
Carlos L. Arteaga, Jeffrey A. Engelman, Youngchul Song, Anindita Chakrabarty, Mónica Valeria Estrada, Archana Narasanna, Ritwik Ghosh, Brent N. Rexer
Supplementary Figure 6 - PDF file 293K, Inhibition of P-Akt in xenografts treated with trastuzumab plus/minus cetuximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::713f0c8d0049cd7e84a289fd82f2fed7
https://doi.org/10.1158/1078-0432.22448759.v1
https://doi.org/10.1158/1078-0432.22448759.v1
Autor:
Carlos L. Arteaga, Jeffrey A. Engelman, Youngchul Song, Anindita Chakrabarty, Mónica Valeria Estrada, Archana Narasanna, Ritwik Ghosh, Brent N. Rexer
Purpose: Mutations in receptor tyrosine kinase (RTK) genes can confer resistance to receptor-targeted therapies. A T798M mutation in the HER2 oncogene has been shown to confer resistance to the tyrosine kinase inhibitor (TKI) lapatinib. We studied th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbcd19e510070b1041872241ab2aae3
https://doi.org/10.1158/1078-0432.c.6521477.v1
https://doi.org/10.1158/1078-0432.c.6521477.v1